New technologies delivered to your inbox Subscribe
The MIT Technology Licenses Office welcomes companies to get to know us personally. We find it most effective to work individually with a company to identify specific areas of interest. We then bring inventions, which specifically match the company's interests to the attention of the company. With 500 new invention disclosures coming into our office each year, our portfolio is constantly changing. The technologies highlighted here do not encompass our entire portfolio. We therefore encourage companies to keep in touch on a regular basis and also to contact us when a particular technology need arises.
Our technology is usually early stage and often requires substantial development by the licensing company before a commercial product is ready for market. Because of this, we often find that the best contact person from the company is one who is knowledgeable about the company's science and technology and also familiar with the long-term strategic plans of the company.
11541 – No summary available
11540 – No summary available
10862 – No summary available
12347 – Nano-sized coatings improve the performance of electrodes in lithium batteries. Lithium batteries have applications ranging from power tools to hybrid electric vehicles. LiMPO4 materials are of interest for rechargeable Li batteries as they are safe, relatively inexpensive and very stable. However, LiMPO4 materials are relatively weak conductors; therefore, they are... Read More
15520 – This invention is a control element for a genetic circuit which allows regulation with tradeoffs and the calculation of the ratio of two input signals. Synthetic biology relies on regulation of gene expression which is difficult for complex functions. This invention is a control element for genetic circuits for predictable programming of biology. This technology is based... Read More
17193 – This invention is a novel combinatorial therapy design for cancer treatment. Though the number of approved cancer therapies has risen dramatically over the past decade, it has become apparent that the efficacy of a single treatment is limited. Combinatorial therapy has become increasingly important, especially in the field of immunotherapy, where engaging multiple responses... Read More
16631 – This invention is an RNA-based genetic circuit which can produce antigens or numerous proteins including: therapeutic, cell death, fluorescent, and selection proteins. This technology may be used for a number of applications including, but not limited to, selective stem cell reprogramming or vaccination.
14427 – This invention may be used to treat protozoan infections like malaria. Many diseases caused by protozoan infection (e.g., malaria, leishmania, giardia, sleeping sickness, amoebic dysentery) are difficult and expensive to treat, use drugs with substantial side effects, or occur in remote regions with little access to facilities such as refrigeration. There is a great need for... Read More
17809 – Programming mammalian cells with large synthetic gene networks can significantly facilitate elucidating complex regulatory cellular mechanisms, implementing new useful biological functions and accelerating the design of novel tailor-made therapeutic treatments. Complex, stable and heritable programming of mammalian cells by genomic engineering is limited by the requirement to... Read More
18577 – This technology increases the potency of cancer vaccines. There is only one FDA approved cancer vaccine, Sipuleucel-T, which only provides a modest survival benefit from prostate cancer. Sipuleucel-T depends on the manipulation of a patient’s own immune cells, and therefore suffers from logistical difficulties that create barriers to its widespread adaptation. Conversely, more... Read More